Pulmatrix's PUR0200 Demonstrated Encouraging Results In Phase 1B Clinical Study In COPD Patients

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix today announced the successful completion and positive results of the second part of a two-part Phase 1B clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate, PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule formulation from the company's novel iSPERSE™ inhaled dry powder technology. The Phase 1B clinical trial compared the pharmacokinetic/pharmacodynamic profile of single doses of PUR0200 to an active comparator or placebo in patients with moderate to severe COPD.

Help employers find you! Check out all the jobs and post your resume.